Understanding how metabolism affects lung cancer progression
Metabolic control of malignant fates in lung cancer
This study is looking at how different ways cancer cells use energy in lung adenocarcinoma, a common type of lung cancer, to see if changing these energy pathways can help make treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11029740 on NIH RePORTER |
What this research studies
This research investigates the role of metabolic pathways in lung adenocarcinoma (LUAD), a common and deadly form of lung cancer. It focuses on how different cell states within tumors may have varying metabolic preferences that influence their ability to progress and resist treatment. By manipulating specific metabolic pathways, particularly the tricarboxylic acid (TCA) cycle, the researchers aim to determine if targeting these pathways can help differentiate or de-differentiate cancer cells, potentially leading to more effective treatments. The study uses both mouse and human cell lines to explore these metabolic configurations and their implications for cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with lung adenocarcinoma, particularly those experiencing treatment resistance.
Not a fit: Patients with other types of lung cancer or those who are not diagnosed with adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that specifically target the metabolic vulnerabilities of lung cancer cells, improving treatment outcomes.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Finley, Lydia — Sloan-Kettering Inst Can Research
- Study coordinator: Finley, Lydia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.